FindTrial
Sign In

Research for Lcn2 as a potential biological marker of neurodegenerative diseases and a possible drug treatment target

Research for Lcn2 as a potential biological marker of neurodegenerative diseases and a possible drug treatment target

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1900025594
Enrollment
Unknown
Registered
2019-09-02
Start date
2019-10-01
Completion date
Unknown
Last updated
2019-09-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neurodegenerative diseases

Interventions

Case series:Nil

Sponsors

Shenzhen Hospital of Southern Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 90 Years

Inclusion criteria

Inclusion criteria: Patients who aged from 40 to 90 years old with neurodegenerative diseases

Exclusion criteria

Exclusion criteria: Patients with serious liver or kidney diseases, cardiovascular diseases, blood diseases and malignant tumors.

Design outcomes

Primary

MeasureTime frame
Lipocalin 2;—

Countries

China

Contacts

Public ContactTian Canhui

Shenzhen Hospital of Southern Medical University

1196014908@qq.com+86 18682043243

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026